Press Release argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Jul 26
Press Release argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update Jul 22